Dr. Reddy

Currently, PostDoc @binghamtonu, working on Antibody-Drug Conjugates. Former scientist @moduleinno, PhD @IISERPUNE, MS @NIPERRaebareli. 🇮🇳🇺🇸

[TumeyLab @TumeyGroup]

https://t.co/d7mKvQvPNw

[TumeyLab @TumeyGroup]

The adoption of ADC technology outside of oncology will almost certainly require subcutaneous (SQ) administration. In the below article, we describe the current state of the field - describing both the promise and the challenges of developing SQ formulations.

[TumeyLab @TumeyGroup]

I’m excited to share our most recent publication describing the development of non-glycosylated (Fc-silent) immune stimulating antibody conjugates (NG-ISACs) for the treatment of TROP2-positive cancers.

[TumeyLab @TumeyGroup]

https://t.co/kKB8WQzNPE

[TumeyLab @TumeyGroup]

Binghamton University is Tackling Childhood Cancer

We are developing a targeted drug delivery system to treat rare childhood cancers—bringing hope for safer, more effective therapies.

[TumeyLab @TumeyGroup]

TAF 2024 Award Winner - L. Nathan Tumey - Binghamton University https://t.co/sdc0Vngrn1 via @YouTube

[TumeyLab @TumeyGroup]

https://t.co/dqs8dWUsdw

[Merck India @MerckIndia]

Experience 2 days of hands-on labs, expert sessions, workshops & real case studies on single-use tech, cGMP & quality. Limited to 20 participants—spots fill fast.

8–9 July 2026 | Register: [email protected] #SingleUseTechnology

[Narendra Modi @narendramodi]

Today, India takes a defining step in its civil nuclear journey, advancing the second stage of its nuclear programme.

The indigenously designed and built Prototype Fast Breeder Reactor at Kalpakkam has attained criticality.

This advanced reactor, capable of producing more fuel than it consumes, reflects the depth of our scientific capability and the strength of our engineering enterprise. It is a decisive step towards harnessing our vast thorium reserves in the third stage of the programme.

A proud moment for India. Congratulations to our scientists and engineers.

[Dr. Reddy @DrReddyPhd]

@TumeyGroup reports a native site-specific method to attach drugs at the Q295 site of mabs. Using TPPMS and a resin-supported strategy, they created uniform and stable Antibody-drug Conjugates (ADCs). #bioconjugation, #ADCs, #Cancer https://t.co/G9ZCxyhHb1

[Dr. Reddy @DrReddyPhd]

@TumeyGroup reports a native site-specific method to attach drugs at the Q295 site of mabs. Using TPPMS and a resin-supported strategy, they created uniform and stable Antibody-drug Conjugates (ADCs). #bioconjugation, #ADCs, #Cancer https://t.co/G9ZCxyhHb1

[TumeyLab @TumeyGroup]

🧬 I'm taking part in an NSF I-Corps program to explore market needs for immune-modulating therapies. Looking to speak with 10–15 folks involved in treating autoimmune diseases or developing related drugs. If you're up for a quick 10–15 min chat, DM me or drop a comment. Thanks!

[Raffaele Colombo @raffcolo]

Preclinical development of DB-1419 published on @CCR_AACR!

DB-1419 is a bispecific ADC (bsADC)
🎯 = B7H3 x PDL1
💊 = P1003 (TOPO1i)
#️⃣ = DAR8

https://t.co/lFJFRADtvR

A mini thread 🧵

[Molecular Cancer Therapeutics @MCT_AACR]

#OnlineFirst: Anti-HER2, High-DAR Antibody Fragment Drug Conjugates (FDC) with a Glucuronide-based MMAE Linker-Payload Demonstrates Superior Efficacy over IgG-based ADCs. https://t.co/xT2aXUDHNW
#HER2 #FirstDisclosure

[Dr. Reddy @DrReddyPhd]

@binghamtonu, @BingPharmacy, @TumeyGroup, Researching the researchers: A look into the school of pharmacy’s post-doctoral program https://t.co/jLQQsU7rof

[The Nobel Prize @NobelPrize]

"Scientists are the working-class noble community, and they are doing everything for the community."

Chemistry laureate David MacMillan speaks on the role of scientists and their contributions to our society.

[Targeted Oncology @TargetedOnc]

The #FDA has granted fast track designation to ADRX-0706, a Nectin-4-targeted ADC, for the treatment of patients with advanced cervical cancer. #gyncsm

https://t.co/KKrJJwms52

[Dr. Reddy @DrReddyPhd]

@binghamtonu, @BingPharmacy, @TumeyGroup, Researching the researchers: A look into the school of pharmacy’s post-doctoral program https://t.co/jLQQsU7rof

[Dr. Reddy @DrReddyPhd]

#AACR25, Wrapping up after an amazing poster session at #AACR2025 — truly inspiring discussions around #ADCs and #CancerResearch! #AACR2025

[Dr. Reddy @DrReddyPhd]

#AACR25, Excited to share that our abstract (@TumeyGroup) received the AACR-John Kincade Scholar-in-Training Award for early-career scientists at #AACR2025!
Incredible ADC talks so far — looking forward to the amazing poster sessions starting today!
#AACR #ADCs #CancerResearch

[Molecular Cancer Therapeutics @MCT_AACR]

Online now. Simultaneous publication with an #AACR25 poster: The #FirstDisclosure of PF-08046032: A Novel, Investigational CD25-Directed Antibody-drug Conjugate Optimized for Selective Depletion of Regulatory T cells in Advanced Malignant Tumors: https://t.co/MVywNTpK1O
@AACR